HK1020529A1 - Use of activated protein c for the treatment of hypercoagulable states associated with sepsis. - Google Patents

Use of activated protein c for the treatment of hypercoagulable states associated with sepsis.

Info

Publication number
HK1020529A1
HK1020529A1 HK99104976A HK99104976A HK1020529A1 HK 1020529 A1 HK1020529 A1 HK 1020529A1 HK 99104976 A HK99104976 A HK 99104976A HK 99104976 A HK99104976 A HK 99104976A HK 1020529 A1 HK1020529 A1 HK 1020529A1
Authority
HK
Hong Kong
Prior art keywords
treatment
activated protein
sepsis
states associated
hypercoagulable states
Prior art date
Application number
HK99104976A
Other languages
English (en)
Inventor
Brian William Grinnell
Daniel Lawrence Hartman
Sau-Chi Betty Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1020529A1 publication Critical patent/HK1020529A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK99104976A 1997-10-20 1999-11-02 Use of activated protein c for the treatment of hypercoagulable states associated with sepsis. HK1020529A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6254997P 1997-10-20 1997-10-20
US6476597P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
HK1020529A1 true HK1020529A1 (en) 2000-05-12

Family

ID=26742406

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99104976A HK1020529A1 (en) 1997-10-20 1999-11-02 Use of activated protein c for the treatment of hypercoagulable states associated with sepsis.

Country Status (28)

Country Link
US (7) US6037322A (id)
EP (2) EP0913156B1 (id)
JP (2) JP3805981B2 (id)
KR (1) KR100798174B1 (id)
CN (1) CN1276726A (id)
AT (1) ATE292979T1 (id)
AU (1) AU748417B2 (id)
BR (1) BR9812965A (id)
CA (1) CA2306983A1 (id)
DE (1) DE69829721T2 (id)
DK (1) DK0913156T3 (id)
EA (1) EA002496B1 (id)
ES (1) ES2239382T3 (id)
HK (1) HK1020529A1 (id)
HU (2) HUP0001237A3 (id)
ID (1) ID24901A (id)
IL (2) IL135712A0 (id)
MY (1) MY117655A (id)
NO (1) NO20002005L (id)
NZ (1) NZ504026A (id)
PL (1) PL200515B1 (id)
PT (1) PT913156E (id)
SI (1) SI0913156T1 (id)
TR (1) TR200001059T2 (id)
TW (1) TWI225404B (id)
UA (1) UA72194C2 (id)
WO (1) WO1999020293A1 (id)
ZA (1) ZA989385B (id)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
BR9809292A (pt) 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
EP1138692A1 (en) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6287516B1 (en) 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
BR9914735A (pt) 1998-10-22 2001-07-03 Lilly Co Eli Processo para tratamento de sépsia
CN1326355A (zh) * 1998-11-13 2001-12-12 伊莱利利公司 治疗肝素诱导的血小板减少症的方法
EP1133314B1 (en) * 1998-11-23 2003-02-19 Eli Lilly And Company Protein c for the treatment of sickle cell disease and thalassemia
AU2001238034A1 (en) 2000-02-04 2001-08-14 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US8535258B2 (en) * 2000-03-24 2013-09-17 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US6736972B1 (en) 2000-03-24 2004-05-18 Immunocept, L.L.C. Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2003528153A (ja) * 2000-03-28 2003-09-24 イーライ・リリー・アンド・カンパニー 活性化プロテインｃを用いた疾患の処置方法
US7576174B2 (en) * 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US8597516B2 (en) * 2000-05-16 2013-12-03 Immunocept, L.L.C. Methods and systems for colloid exchange therapy
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
AU2001262939A1 (en) * 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
PL362414A1 (en) 2001-02-19 2004-11-02 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
JP4351041B2 (ja) * 2001-06-13 2009-10-28 ザ・ユニバーシティ・オブ・シドニー 傷治癒のための処置および組成物
US20030055003A1 (en) * 2001-07-19 2003-03-20 David Bar-Or Use of copper chelators to inhibit the inactivation of protein C
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
PL374506A1 (en) 2001-10-15 2005-10-31 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
EP1545690A4 (en) * 2002-08-13 2006-04-12 Arbios Systems Inc SELECTIVE PLASMA EXCHANGE THERAPY
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
EP1598368A4 (en) * 2003-01-20 2007-07-25 Chugai Pharmaceutical Co Ltd ANTI-PCI neutralizing ANTIBODY
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
EP2266606B1 (en) 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1651252B1 (en) * 2003-07-08 2014-11-26 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
US20090227669A1 (en) * 2004-01-23 2009-09-10 The University Of Toledo Compositions and Methods for Perioperative Bladder Instillation
CA2560103A1 (en) * 2004-03-17 2005-11-24 Chiron Corporation Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
CA2566411A1 (en) * 2004-05-11 2005-11-24 Heptest Laboratories, Inc. Compositions, kit and one-step method for monitoring compounds having anti-factor xa and/or anti factor iia activities
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
WO2006124770A2 (en) * 2005-05-13 2006-11-23 The Feinstein Institute For Medical Research Treatment of sepsis and inflammation with alpha2a adrenergic antagonists
JP2008543925A (ja) * 2005-06-24 2008-12-04 ダラグレキュル・アンパルトセルスカブ 呼吸器系に影響を及ぼす炎症状態における組織因子系凝固インヒビターの気道投与
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
EP2078074A4 (en) * 2006-10-31 2011-09-28 Scripps Research Inst DOSAGE SCHEME OF ACTIVATED PROTEIN C AND ITS VARIANTS WITH REDUCED ANTICOAGULANT ACTIVITY
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
RU2490722C1 (ru) * 2012-04-24 2013-08-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Способ восстановления кровотока в регионе тромбированной вены в эксперименте
RU2662564C2 (ru) 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
JP7277484B2 (ja) 2018-06-15 2023-05-19 エービー サンドビック マテリアルズ テクノロジー 二相ステンレス鋼ストリップおよびそれを製造するための方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
JP3434326B2 (ja) * 1992-08-25 2003-08-04 財団法人化学及血清療法研究所 成人呼吸窮迫症候群（ａｒｄｓ）予防、治療剤
JP2825739B2 (ja) * 1993-09-20 1998-11-18 帝人株式会社 急性肝不全治療剤
JP3802104B2 (ja) * 1995-05-31 2006-07-26 財団法人化学及血清療法研究所 脊髄損傷に伴う神経障害の予防・治療剤
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
BR9809292A (pt) * 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
DE69829721T2 (de) 2006-02-09
HUP0001237A3 (en) 2002-01-28
CN1276726A (zh) 2000-12-13
DE69829721D1 (de) 2005-05-19
EA002496B1 (ru) 2002-06-27
ZA989385B (en) 2000-04-14
CA2306983A1 (en) 1999-04-29
EP0913156A1 (en) 1999-05-06
EP0913156B1 (en) 2005-04-13
BR9812965A (pt) 2001-03-20
EP1449537A2 (en) 2004-08-25
SI0913156T1 (en) 2005-10-31
US6008199A (en) 1999-12-28
ATE292979T1 (de) 2005-04-15
US6037322A (en) 2000-03-14
TWI225404B (en) 2004-12-21
KR100798174B1 (ko) 2008-01-24
US6268344B1 (en) 2001-07-31
JP3805981B2 (ja) 2006-08-09
HUP0100025A3 (en) 2003-08-28
HUP0100025A2 (hu) 2001-05-28
WO1999020293A1 (en) 1999-04-29
TR200001059T2 (tr) 2000-10-23
JP2001520199A (ja) 2001-10-30
US6426071B2 (en) 2002-07-30
EA200000445A1 (ru) 2000-10-30
ES2239382T3 (es) 2005-09-16
US6489296B1 (en) 2002-12-03
PT913156E (pt) 2005-08-31
IL135712A0 (en) 2001-05-20
PL340096A1 (en) 2001-01-15
UA72194C2 (en) 2005-02-15
PL200515B1 (pl) 2009-01-30
DK0913156T3 (da) 2005-06-27
HUP0001237A2 (hu) 2000-08-28
KR20010031217A (ko) 2001-04-16
JP2005097313A (ja) 2005-04-14
MY117655A (en) 2004-07-31
US20010036456A1 (en) 2001-11-01
US6268337B1 (en) 2001-07-31
AU748417B2 (en) 2002-06-06
NZ504026A (en) 2002-12-20
EP1449537A3 (en) 2005-09-21
NO20002005L (no) 2000-05-16
NO20002005D0 (no) 2000-04-17
ID24901A (id) 2000-08-31
IL135712A (en) 2010-12-30
US6156734A (en) 2000-12-05
AU9804098A (en) 1999-05-10
HU224901B1 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
HK1020529A1 (en) Use of activated protein c for the treatment of hypercoagulable states associated with sepsis.
WO1997036609A3 (en) Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
EP1019072A4 (en) ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
HUP0003256A2 (hu) Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
ID23176A (id) Metoda untuk mengobati gangguan pembuluh darah
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
RU2099061C1 (ru) Способ лечения нейродермита
SE9101341D0 (sv) New medicinal use
RU2193884C2 (ru) Способ премедикации больных с сердечно-сосудистой патологией при амбулаторных стоматологических вмешательствах
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
RU95102346A (ru) Способ лечения дисциркуляторной энцефалопатии
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
RU2002133046A (ru) Фармацевтическая композиция, содержащая фактор viia и фактор xiii
RU97110054A (ru) Способ лечения синдрома "диабетическая стопа"
UA19596A (uk) Спосіб лікуваhhя гіпертоhічhої хвороби гірудорефлексотерапією
MX9603833A (es) Tratamiento mejorado del cancer con temozolomida.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121015